A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia

Infection

Volumn 35, Issue 6, 2007, Pages 414-420

  Hoffken G ^a   Barth, J ^b   Rubinstein, E ^c   Beckmann, H ^d  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b BG KLINIKEN BERGMANNSTROST   (Germany)

^c UNIVERSITY OF MANITOBA   (Canada)

^d BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CEFUROXIME AXETIL; MOXIFLOXACIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BLOOD DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEART ARRHYTHMIA; HEART DISEASE; HOSPITAL INFECTION; HUMAN; KIDNEY DISEASE; LUNG EMBOLISM; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; NEUROLOGIC DISEASE; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; VASCULAR DISEASE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIA; CEFTRIAXONE; CEFUROXIME; CROSS INFECTION; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; QUINOLINES; TREATMENT OUTCOME;

EID: 37449018639     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-6193-x     Document Type: Article

References (14)

1. American Thoracic Society: Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, preventive strategies. A consensus statement, November 1995. Am J Respir Crit Care Med 1996; 153: 1711-1725.
2. Cunnion KM, Weber DJ, Broadhead WE, Hanson LC, Pieper CF, Rutala WA: Risk factors for nosocomial pneumonia: comparing adult critical-care populations. Am J Respir Crit Care Med 1996; 153: 158-162.
3. Niederman MS: Appropriate use of antimicrobial agents: challenges and strategies for improvement. Crit Care Med 2003; 31: 608-616.
4. Harmanci A, Harmanci O, Akova M: Hospital-acquired pneumonia: challenges and options for diagnosis and treatment. J Hosp Infect 2002; 51: 160-167.
5. Fiel S: Guidelines and critical pathways for severe hospital-acquired pneumonia. Chest 2001; 119: 412S-418S.
6. Leone M, Albanese J, Sampol-Manos E, Simon N, Lacarelle B, Bruguerolle B, Martin C: Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia. Antimicrob Agents Chemother 2004; 48: 638-640.
7. Welte T, Petermann W, Schürmann D, Bauer TT, Reimnitz PMOXIRAPID Study Group: Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41: 1697-1705.
8. Katz E, Larsen LS, Fogarty CM, Hamed K, Song J, Choudhri S: Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med 2004; 27: 395-405.
9. EMEA. Committee for proprietary medicinal products (CPMP): Note on guidance on evaluation of medicinal products indicated for treatment of bacterial infections. 2004. http://www.emea.europa.eu/pdfs/human/ewp/055895en. pdf.
10. American Thoracic Society: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
11. Blondeau JM, Hansen GT: Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. Expert Opin Pharmacother 2001; 2: 317-335.
12. Torres A, Bauer TT, Leon-Gil C, Castillo F, Alvarez-Lerma F, Martinez-Pellus A, Leal-Noval SR, Nadal P, Palomar M, Blanquer J, Ros F: Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000; 55: 1033-1039.
13. Finch R, Schurmann D, Collins O, Kubin R, McGivern J, Bobbaers H, Izquierdo JL, Nikolaides P, Ogundare F, Raz R, Zuck P, Hoeffken G: Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with communityacquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746-1754.
14. Lamb HM, Ormrod D, Scott LJ, Figgitt DP: Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs 2002; 62: 1041-1089.